Boston Scientific (NYSE:BSX) announced that it completed its acquisition of Preventice Solutions that could be worth up to $1.225 billion. The transaction includes a cash payment of $925 million upfront with up to an additional $300 million in potential commercial milestone payments available. Accounting for the company’s approximately 22% equity stake in Preventice prior to the […]
BTG
Boston Scientific to sell BTG Specialty Pharmaceuticals for $800M
Boston Scientific (NYSE:BSX) announced today that it entered into a definitive agreement to sell its BTG Specialty Pharmaceuticals business. Marlborough, Mass.-based Boston Scientific is selling BTG for $800 million in cash to Stark International Lux S.A.R.L. and SERP SAS, both affiliates of European specialty pharmaceutical group SERB, according to a news release. SERB, which is backed […]
Boston Scientific sells Zytiga royalties for $256m
Boston Scientific (NYSE:BSX) has sold half of its Zytiga-related royalties to Ontario Municipal Employees Retirement System for $256 million. The deal is worth 50% of the Zytiga-related royalties, according to an SEC Form 8-K filing from yesterday. Zytiga is a treatment for men with metastatic castration-resistant prostate cancer, according to its website. The sale begins with […]
Varian closes $90m microspheres buy from Boston Scientific
Hot on the heels of the $4 billion buyout of BTG by Boston Scientific (NYSE:BSX), Varian (NYSE:VAR) said yesterday that it closed the $90 million acquisition of Boston’s microspheres business. The deal for the drug-eluting and “bland” embolic microsphere business, which includes the Oncozene, Embozene and Embozone Tandem products, was struck to mollify anti-trust regulators about the BTG […]
Delcath Systems raises another $9.5m
Delcath Systems (OTC:DCTH) has closed on a $9.5 million private placement round, bringing the total amount raised since July to $29.5 million. The Queensbury, N.Y.-based company priced the round at $1,000 per unit, with each unit consisting of a preferred convertible share worth 16,667 common shares, at a 6¢ strike price, and a five-year warrant for […]
Boston Scientific closes $4B BTG purchase
Boston Scientific (NYSE:BSX) said today that it finished its $4 billion acquisition of BTG (LN:BTG). The Marlborough, Mass.-based medtech giant reported that the transaction will be immaterial to adjusted earnings per share this year, thanks to – among other factors – the deal closing later than initially anticipated. To satisfy antitrust regulators, Boston Scientific is […]
UK regulators OK Boston Scientific’s $4B BTG buyout
British regulators have approved Boston Scientific’s (NYSE:BSX) $4 billion bid to buy BTG (LN:BTG), the companies announced today in regulatory filings. The deal, approved by the U.S. Federal Trade Commission on August 7, will close on Monday. The High Court of Justice in England and Wales agreed to the takeover following a hearing today. Boston […]
FTC clears Boston Sci’s $4B purchase of BTG
The Federal Trade Commission has approved Boston Scientific’s $4 billion acquisition of British medtech company BTG (LON:BTG), according to a regulatory filing. Other antitrust authorities, such as the Federal Competition Authority of Austria and the National Authority for Markets and Competition in Spain, cleared the takeover in the past few weeks, according to the filing. […]
Boston Scientific to deal microspheres to Varian Medical for $90m
UPDATED July 2, 2019, with financial details, comment from Varian. Looking to mollify anti-trust regulators about its pending $4 billion merger with BTG (LON:BTG), Boston Scientific (NYSE:BSX) said today that it agreed to deal its microsphere assets to Varian Medical (NYSE:VAR) for $90 million. The deal for the drug-eluting and “bland” embolic microsphere business includes Marlborough, Mass.-based Boston […]
BTG shareholders OK $4B Boston Scientific buyout
BTG (LON:BTG) said yesterday that its shareholders voted to approve a more than $4 billion buyout offer by Boston Scientific (NYSE:BSX) and affirmed that the deal is on track to close mid-year. The British medical device maker said that some 95.4% of the shareholders affected by the tie-up voted for the deal, with 4.6% of those shares voting against. […]
Boston Scientific closes $4B debt offering for BTG buyout
Boston Scientific (NYSE:BSX) said yesterday that it closed a $4.3 billion debt round it plans use to defray the cost of buying BTG (LON:BTG). The Marlborough, Mass.-based medical device company said the flotation comprised $850 million worth of 3.45% notes due 2024, $850 million in 3.75% notes due 2026, $850 million of 4.0% notes due 2029, $750 million of […]
